Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Scapular Dyskinesis With Impingement Syndrome

NCT07001228 · tracked via the Priya Life Science South Korea tracker
Phase
Not applicable
Started
2025-05-29
Last updated
2025-06-06

Condition(s) studied

Scapular DyskinesisImpingement Syndrome, Shoulder

Investigational drug(s) / intervention(s)

SD rehabilitationNo SD rehabilitation

SD rehabilitation: For shoulder impingement syndrome, the standard rehabilitation protocol involves administering a subacromial steroid injection at the initial outpatient visit, followed by stick exercises to restore joint mobility starting three weeks later. Four weeks after initiating the stick exercises, rotator cuff strengthening exercises using therabands are introduced and maintained for a duration of six weeks. For SD rehabilitation, shoulder external rotation, push up plus, and shoulder rolls were performed. In the experimental group, rehabilitation for scapular dyskinesis will begin at the second outpatient visit, which takes place three weeks after the subacromial steroid injection.

No SD rehabilitation: For shoulder impingement syndrome, the standard rehabilitation protocol involves administering a subacromial steroid injection at the initial outpatient visit, followed by stick exercises to restore joint mobility starting three weeks later. Four weeks after initiating the stick exercises, rotator cuff strengthening exercises using therabands are introduced and maintained for a duration of six weeks. In the sham group, rehabilitation for scapular dyskinesis will not begun at the second outpatient visit, which takes place three weeks after the subacromial steroid injection.

Study summary

The goal of this study is to diagnose scapular dyskinesis-which can appear as a cause or result of various shoulder disorders-through screening tests in patients with shoulder impingement syndrome, the most common shoulder condition. By identifying scapular dyskinesis, the study aims to maximize treatment outcomes through appropriate rehabilitative exercise therapy.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
1. Inclusion Criteria Patients diagnosed with unilateral shoulder impingement syndrome in the outpatient clinic (based on clinical symptoms and MRI) from the IRB approval date until March 1, 2027 Individuals who provided written informed consent after receiving a thorough explanation of the study prior to any procedures Age 20 years or older 2. Exclusion Criteria Individuals who did not receive a subacromial steroid injection for shoulder impingement syndrome Individuals with a history of surgical treatment or fracture in the affected shoulder Individuals who refused to participate in the study Individuals with neurological disorders affecting the ipsilateral upper extremity

Primary outcome measure(s)

  • visual analog pain scale (VAS) — Initial, 3, 7, 13 weeks
    0-10, 0: not satisfied, 10: very much satisfied

Trial sites (1)

FacilityCityRegionStatus
Hallym University Chuncheon Sacred Heart Hospital Chuncheon Gangwon-do
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07001228 on ClinicalTrials.gov ↗ ← All trials in South Korea